Equities research analysts forecast that Sanofi SA (NYSE:SNY) will report earnings of $0.68 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Sanofi’s earnings. The highest EPS estimate is $0.71 and the lowest is $0.66. Sanofi posted earnings of $0.67 per share during the same quarter last year, which would suggest a positive year over year growth rate of 1.5%. The firm is expected to announce its next quarterly earnings report before the market opens on Wednesday, February 7th.

According to Zacks, analysts expect that Sanofi will report full-year earnings of $3.34 per share for the current year, with EPS estimates ranging from $3.18 to $3.45. For the next financial year, analysts anticipate that the company will post earnings of $3.42 per share, with EPS estimates ranging from $3.24 to $3.66. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Sanofi.

Sanofi (NYSE:SNY) last posted its earnings results on Thursday, November 2nd. The company reported $1.00 EPS for the quarter, meeting the consensus estimate of $1.00. The firm had revenue of $10.63 billion during the quarter, compared to the consensus estimate of $10.93 billion. Sanofi had a return on equity of 25.19% and a net margin of 25.44%.

Several equities analysts have commented on SNY shares. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Morgan Stanley cut Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $51.50.

Several hedge funds have recently modified their holdings of SNY. Southpoint Capital Advisors LP acquired a new stake in shares of Sanofi in the second quarter valued at about $57,492,000. BlackRock Inc. grew its stake in Sanofi by 47.6% during the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock worth $107,100,000 after purchasing an additional 720,523 shares during the period. Boston Partners grew its stake in Sanofi by 6.2% during the third quarter. Boston Partners now owns 8,664,983 shares of the company’s stock worth $431,429,000 after purchasing an additional 503,799 shares during the period. Janus Henderson Group PLC acquired a new stake in Sanofi during the second quarter worth approximately $22,558,000. Finally, Fisher Asset Management LLC grew its stake in Sanofi by 3.3% during the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock worth $701,156,000 after purchasing an additional 443,799 shares during the period. 9.08% of the stock is owned by institutional investors.

Sanofi (NYSE:SNY) traded up $0.09 during trading on Friday, reaching $44.60. The company’s stock had a trading volume of 1,897,864 shares, compared to its average volume of 1,290,000. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $112,600.00, a P/E ratio of 20.18, a PEG ratio of 2.43 and a beta of 0.86. Sanofi has a 1 year low of $39.42 and a 1 year high of $50.65.

COPYRIGHT VIOLATION WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/01/21/brokerages-expect-sanofi-sa-sny-will-post-earnings-of-0-68-per-share.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Get a free copy of the Zacks research report on Sanofi (SNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.